You're contacting media contact of this press release

Title: Paul Grtner Leads Cellise GmbH in Advancing Regenerative Medicine Through Innovative Stem Cell Harvesting

Basel, Switzerland, 26th Jun 2025 – In the heart of Switzerland’s life sciences hub, Paul Gärtner, Managing Director of Cellise GmbH, is spearheading a transformative approach to regenerative medicine. His company specializes in the collection, purification, and cryopreservation of stem cells derived from umbilical cord blood and placental tissue—harvested during childbirth in collaboration with select partner hospitals.With the growing global demand for advanced therapeutic solutions, Cellise’s mission is to unlock the untapped potential of neonatal stem cells for cutting-edge research and life-saving medical treatments. Under Gärtner’s leadership, the company has established key relationships with leading pharmaceutical firms and academic institutions to drive innovation in the fields of oncology, immunology, and tissue regeneration.A Vision Rooted in Scientific AdvancementPaul Gärtner, an entrepreneur with a strong background in biotech ventures, is passionate about improving human health through scientific progress. At Cellise, he oversees operations that focus on ethical, consent-based stem cell harvesting, followed by a rigorous purification and preservation process. The resulting stem cell units are stored under cryogenic conditions, maintaining their viability for future use in medical research and treatment."Our vision is to build a bridge between childbirth and cure," said Gärtner. "By preserving these powerful biological resources at the moment of birth, we are creating a path to healthier futures for individuals and populations alike."Strategic Partnerships to Accelerate Medical BreakthroughsRecognizing the critical role of collaboration in biotech development, Cellise has forged strategic partnerships with renowned research institutes and pharmaceutica...

This press release is issued by King Newswire